Leptomeningeal Metastases (LM) is sometimes referred to as leptomeningeal cancer, leptomeningeal disease, neoplastic meningitis, or meningeal carcinomatosis. This rare but serious condition happens when cancer cells spread to the membranes surrounding the brain and spinal cord.  Leptomeningeal Metastases is most commonly found in patients with melanoma, breast, lung, or gastrointestinal cancer. Unfortunately, there are no FDA approved treatments specifically for Leptomeningeal Metastases.

Plus Therapeutics is developing a new targeted radiation therapy, REYOBIQ™ (rhenium Re186 obisbemeda), for central nervous system cancers such as Leptomeningeal Metastases.  In the U.S. ReSPECT-LM clinical trial, doctors will give Leptomeningeal Metastases patients a single dose of REYOBIQ™ through a small catheter placed under the patient’s scalp. This drug will be administered in less than 5 minutes in a hospital setting and the patient will go home the same day.

The ReSPECT-LM clinical trial is funded, in part, by a $17.6 million grant from the Cancer Prevention & Research Institute of Texas, the second largest public funding source for cancer research in the world.

View Trial on ClinicalTrials.gov

View the ReSPECT-LM Trial Guide for Patients